Two-year outcomes of thymoglobulin versus basiliximab induction combined with sirolimus and reduced-dose cyclosporine (CsA) for high versus low risk immune responder renal transplant recipients.

被引：0
|
作者：
Knight, RJ [1 ]
Kerman, RH [1 ]
Schoenberg, L [1 ]
Podder, H [1 ]
Katz, SM [1 ]
Van Buren, CT [1 ]
Kahan, BD [1 ]
机构：
[1] Univ Texas, Sch Med, Houston, TX USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2005年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
124
引用
收藏
页码：188 / 188
页数：1
相关论文
共 6 条
  • [1] Four-year outcomes comparing thyrnoglobulin and basiliximab in combination with sirolimus and reduced-dose cyclosporine for high versus low risk immune responders.
    Knight, Richard J.
    Schoenberg, Linda
    Kerman, Ronald H.
    Podder, Hemangshu
    Katz, Stephan
    Van Buren, Charles T.
    Kahan, Barry D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 520 - 520
  • [2] The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function
    Knight, RJ
    Kerman, RH
    Schoenberg, L
    Podder, H
    Van Buren, CT
    Katz, S
    Kahan, BD
    TRANSPLANTATION, 2004, 78 (06) : 904 - 910
  • [3] Outcomes in Obese Renal Transplant Recipients Using High versus Low-Dose Thymoglobulin.
    Jasiak, N.
    Stromayer, C.
    Thielke, J.
    Chen, J.
    Chen, J.
    Talon, B.
    Rubin-Tobar, R.
    Benedetti, E.
    West-Thielke, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 618 - 618
  • [4] Low-Dose Thymoglobulin versus Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: Three-Year Follow-Up Study
    Martinez-Mier, Gustavo
    Moreno-Ley, Pedro I.
    Budar-Fernandez, Luis F.
    Mendez-Lopez, Marco T.
    Allende-Castellanos, Carlos A.
    Jimenez-Lopez, Luis A.
    Barrera-Amoros, Daniel A.
    Reyes-Ruiz, Jose Manuel
    ARCHIVES OF MEDICAL RESEARCH, 2024, 55 (06)
  • [5] Low-Dose Rabbit Antithymocyte Globulin Versus Basiliximab Induction Therapy in Low-Risk Renal Transplant Recipients: 8-Year Follow-Up
    Laftavi, M. R.
    Alnimri, M.
    Weber-Shrikant, E.
    Kohli, R.
    Said, M.
    Patel, S.
    Pankewycz, O.
    TRANSPLANTATION PROCEEDINGS, 2011, 43 (02) : 458 - 461
  • [6] Prevention of cytomegalovirus disease in moderate-risk (D+/R+ and D-/R+) renal transplant recipients receiving basiliximab induction therapy: an efficacy and safety evaluation of 3 versus 6 months of low-dose valganciclovir
    Gabardi, Steven
    Cross, Rosemary
    DePiero, Kelly
    Dick, Travis B.
    Maxwell, Pamela R.
    Nelson, Joelle
    Newkirk, Erin N.
    Kathleen Nguyen
    Park, Jeong M.
    Tichy, Eric M.
    Ueda, Kimi
    Weng, Renee
    Maldonado, Angela Q.
    PHARMACOTHERAPY, 2012, 32 (10): : E249 - E249
1